The vaccine, called CoronaVac, induced neutralizing antibodies in more than 90 percent of trial participants two weeks after they received the jab. 'Our Phase I/II study shows CoronaVac is safe and can induce immune response,' Sinovac CEO, chairman and president Weidong Yin said in a statement. 'Concluding our Phase I/II clinical studies with these encouraging results is another significant milestone we have achieved in the fight against COVID-19.' Sinovac is preparing to soon submit its Phase II results and plans for Phase III trials to China's National Medical Products Administration as well as applications for Phase III trials in international countries. Last week, the company announced it was partnering with São Paulo-based Instituto Butantan to begin Phase III CoronaVac trials in Brazil.

Source: Daily Mail June 15, 2020 20:26 UTC